Emmecell Announces FDA Acceptance of IND Application for EO2002 in Corneal Edema
- Tuesday, September 22, 2020, 7:01
- Finance
- Add a comment
MENLO PARK, Calif., Sept. 22, 2020 /PRNewswire/ — Emmetrope Ophthalmics LLC (“Emmecell”), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of eye diseases, today announced that the U.S. Food and Drug Administration…
About the Author
adminasapcorp has written 39073 stories on this site.